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Abstract: Significant progress in the manufacturing of biopharmaceuticals has been made by
increasing the overall titers in the USP (upstream processing) titers without raising the cost of
the USP. In addition, the development of platform processes led to a higher process robustness.
Despite or even due to those achievements, novel challenges are in sight. The higher upstream titers
created more complex impurity profiles, both in mass and composition, demanding higher separation
capacities and selectivity in downstream processing (DSP). This creates a major shift of costs from USP
to DSP. In order to solve this issue, USP and DSP integration approaches can be developed and used
for overall process optimization. This study focuses on the characterization and classification of host
cell proteins (HCPs) in each unit operation of the DSP (i.e., aqueous two-phase extraction, integrated
countercurrent chromatography). The results create a data-driven feedback to the USP, which will
serve for media and process optimizations in order to reduce, or even eliminate nascent critical
HCPs. This will improve separation efficiency and may lead to a quantitative process understanding.
Different HCP species were classified by stringent criteria with regard to DSP separation parameters
into “The Good, the Bad, and the Ugly” in terms of pI and MW using 2D-PAGE analysis depending
on their positions on the gels. Those spots were identified using LC-MS/MS analysis. HCPs,
which are especially difficult to remove and persistent throughout the DSP (i.e., “Bad” or “Ugly”),
have to be evaluated by their ability to be separated. In this approach, HCPs, considered “Ugly,”
represent proteins with a MW larger than 15 kDa and a pI between 7.30 and 9.30. “Bad” HCPs can
likewise be classified using MW (>15 kDa) and pI (4.75–7.30 and 9.30–10.00). HCPs with a MW
smaller than 15 kDa and a pI lower than 4.75 and higher than 10.00 are classified as “Good” since
their physicochemical properties differ significantly from the product. In order to evaluate this
classification scheme, it is of utmost importance to use orthogonal analytical methods such as IEX,
HIC, and SEC.
Keywords: upstream; downstream; host cell protein; CHO; ATPE; iCCC
1. Introduction
The amounts of biotechnology products produced worldwide, prescription as well as
over-the-counter drugs, are estimated to account for around 50% of the most successful pharmaceutical
products by the year 2020 [1]. Oncology constitutes the biggest therapeutic sector, with an annual
growth rate of around 12.5% and sales of approximately $83.2 billion in 2015. Among the five top-selling
oncological products, three will be monoclonal antibodies by the year 2020 [2]. The manufacturing
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process of biopharmaceuticals such as monoclonal antibodies (e.g., IgG, immunoglobulin G) is divided
into upstream (USP) and downstream processing (DSP) [3–8]. The production of the monoclonal
antibody in bioreactors (BR) using mammalian cells as an expression host and the separation of the
liquid phase from the cells using centrifuges or filters is defined as USP [9]. The subsequent DSP
is designed to separate side components like host cell proteins (HCP) or host cell DNA (hDNA)
from the main component [6,7,10]. The most common unit operations used in the DSP are typically
chromatography and filtration.
The commercial success of monoclonal antibodies of course led to significantly increased demand
in their production scale [11]. Coping with these demands without significantly changing the approved
manufacturing facilities almost forced companies to follow the route of increasing titers within the
existing facilities.
Hence, compared to earlier yields of a couple of grams per liter, today antibody concentrations
of up to 25 g/L can be achieved using a modified perfusion process [12,13]. Routinely, antibody
concentrations of between three and five grams per liter can be generated in fed-batch
processes [3,14,15]. However, increasing product titers at constant volumes due to higher cell
concentrations will lead to capacity limitations in the DSP, which has to be compensated for by
longer process times, higher material consumption, and corresponding costs [4]. This will significantly
shift the cost of goods from the USP to the DSP [5]. Therefore, DSP technologies are required that
circumvent this upcoming “downstream bottleneck,” handling high titer volumes [4,16,17].
Optimizations in the USP concepts have led to increasing product titers. Along with this, raised
impurity profiles have been observed [8,9]. Various compositions of the cultivation broth present
challenges in the DSP of biotechnologically produced proteins. Considering the generic platform
production process for antibodies, unit operations like centrifugation, micro- and ultrafiltration,
protein A affinity chromatography, two orthogonal virus inactivation steps, ion-exchange (IEX),
and hydrophobic interaction chromatography (HIC) are being used [5]. For the characterization of
protein purification stages, key performance parameters can be used. These are typically resolution,
speed, recovery, and capacity, as seen in Figure 1.
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The  objectives  vary  depending  on  the  purification  stage  in  focus,  and  therefore  generate 
different challenges  that have  to be addressed during process optimization  [18]. For example,  the 
i . f ce para eters of the capture, intermediate purification, and polishing step for
protein purifications according to [18].
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The objectives vary depending on the purification stage in focus, and therefore generate different
challenges that have to be addressed during process optimization [18]. For example, the protein A
affinity chromatography, used as a capture step, will reach its capacity limitation due to increasing
product titers. This can be problematic since this criterion characterizes the capture step and is one
of its two objectives. Moving downstream, selectivity challenges occurring during the intermediate
purification and polishing step will prevent each step from reaching one of its objectives. Selectivity
challenges are going to affect the resolution in IEX and HIC separation operations when HCP resemble
the product in terms of pI and hydrophobicity, respectively [12,18].
Impurities like HCPs, which resemble the desired product only in one characteristic (e.g., pI),
may challenge the IEX but can probably be easily separated from the product by an additional
chromatographic step (e.g., HIC). Impurities similar to the product in more than one characteristic
(e.g., pI and hydrophobicity) will be troublesome during purification and polishing. Therefore, the
pI and hydrophobic distribution of the impurity spectrum can negatively affect IEX and HIC
separations, respectively.
Critical performance parameters regarding the separation efficiency during the capture of
monoclonal antibodies using affinity chromatography are capacity limitations as well as (un-)specific
HCP co-elution [19]. Consequently, new approaches and technology are needed in order to circumvent
future bottlenecks and separation challenges [4].
Furthermore, the existing challenges in process engineering have worsened since regulatory
agencies demand higher product quality, an advanced understanding of the process and product,
as well as batch-independent product quality [20–22]. Bioprocess engineering will probably focus in
regulated industries on quality by design and process analytical technology mechanisms, in order to
design, analyze, and control manufacturing processes [23]. This shall lead to improved process control
by knowledge-based and statistical methods, which ultimately guarantees the process’ robustness.
For example, monoclonal antibodies and fragments represent an interesting group of
biopharmaceuticals due to their broad field of application (e.g., analysis or diagnostic).
Those glycoproteins are structurally complex and differ in various formats, as can be seen in Figure 2.







Figure 2. Various formats of recombinant antibodies [24].
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The post-translational modifications, especially glycosylations, of these proteins are of utmost
importance for their correct function [20]. The immense diversity of glycosylation patterns impacts
the functionality, immunogenicity, and pharmacokinetics of the antibody [24,25]. Due to this,
posttranslational modifications should be considered critical quality attributes (CQA) and verified
throughout the manufacturing of monoclonal antibodies [26–30]. Antibody N-glycans can be
quantitatively determined by normal phase chromatography after N-glycosidase digestion and glycan
labeling, for example [31]. The most prevalent N-linked glycosylation patterns at the Cγ2 domain of
the heavy chain (Fc) of an immunoglobulin G (IgG) are depicted in Figure 3, where the most common







Figure 3. Common glycosylation patterns of an IgG. (A) high mannose content; (B) hybrid; (C) complex
biantennary oligosaccharide with core fucosylation; (D) most prevalent oligosaccharide structures of
IgG [20].
Besides critical process parameters (CPP) like pH, pO2 and pCO2, more often impurities play
an important role in affecting CQA of the biopharmaceutical product. For example, extracellular
proteases and glycosidases accumulating during the cultivation negatively influence the CQA of
monoclonal antibodies [14,32–35]. The impurity spectrum consists of a multiplicity of different
substances (HCP, hDNA, virus, cells, and cell debris). In this integration approach, HCPs are considered
as the primary impurity based on their broad composition and range of isoelectric point (pI), molecular
weight (MW), and hydrophobicity, as can be seen in Table 1 [36–40]. They exhibit no constant
level, composition, or property distribution. HCPs caused by secretion or cell lysis can range in pI
(2–11), MW (10–200 kDa), and variable hydrophobicity, and are therefore difficult to separate if their
physicochemical properties resemble the product of interest.
Table 1. Physicochemical properties of the main impurities during the production of
biopharmaceuticals, according to [38].
Class pI MW (kDa) Hydrophobicity Origin Cause
HCP 2–11 10–200 Variable Host cells Secretion, lysis
hDNA 2–3 90–1000 Low Host cells Lysis
Insulin 5.3–5.5 5.8 Low Media Supplement
Virus 4–7.5 200–7200 Variable Host cells, media Contamination
Endotoxins 1–4 3–40 Variable Media, contamination Contamination
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Primary recovery and purification steps for a biopharmaceutical DSP are based on
physicochemical properties in order to efficiently purify the product. However, especially in the
case of increasing product titers, a sub-population of impurities (i.e., HCP), which negatively affect the
product quality, may remain with the desired protein and represent a certain risk [40]. Therefore, it is
of critical importance to validate qualitatively and quantitatively the separation efficiency of each unit
operation in the DSP.
This assessment will lead to an expanded understanding of each unit operation by classifying the
impurities into “The Good, the Bad, and the Ugly”:
• Impurities, which can be separated easily from the main component, are considered “the Good.”
They possess physicochemical properties significantly different from the protein of interest (i.e., pI,
MW, hydrophobicity). As a result, they may be separated by only one unit operation in an efficient
way (ion exchange in terms of charge differences).
• Side components showing more similarity to the product are more difficult to separate or are
persistent throughout (i.e., not separable from the product) and thus are considered as “the Bad”
or “the Ugly.”
By characterizing the HCP criteria for an efficient DSP, it is possible to gain a deeper understanding
of the process and preserve the quality of the product. This categorization can be used for an USP
DSP integration approach towards an efficient production process by circumventing the generation or
accumulation of “Bad” and “Ugly” impurities (Figure 4).
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Figure 4. USP DSP integration approach for a systematic development of a bioprocess.
The considered process for the production of monoclonal antibodies utilizes mammalian cell
cultivations. Afterwards, the aqueous two-phase extraction (ATPE) is used as a c ll harvesting or
capture step, epe ding on the system compos tion used [41–45]. Follow ng the ATPE, the integrated
counter current chromatography (iCCC), which is a co bination of an IEX and HIC, is employed as
a purification and polishing step. This combination of chromatographic columns leads to a highly
purified product [46].
The integration approach begins with a data-driven characterization of HCP occurring in the broth
and in each unit operation. The separation efficiency is determined by analytical methods (i.e., 2D
SDS-PAGE, SEC, IEX, HIC, and HPLC-MS/MS). The SEC chromatograms qualitatively describe the
impurity spectrum and can be used for a determination of impurities in the molecular weight range
of the considered product (150 kDa). The IEX and HIC are used for ch racter zing the charge and
hydrophobicity of e HCPs. 2D SDS-PAGE analysis, combined with HPLC-MS/MS measurements,
is used for the identification and, of utmost importance, classification of “The Good, the Bad, and
the Ugly” HCPs. This classification is done by evaluating the molecular weight, isoelectric point,
and hydrophobicity of the HCPs, as seen in Table 2.
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Afterwards, these findings are used in rational process design in order to minimize or even
eliminate “Ugly” HCPs, which cannot be easily separated from the product (Figure 4).
Table 2. Analytical methods used for the characterization of HCP.
Characteristic Method Orthogonal Method
Isoelectric point 2D-SDS PAGE IEX; HPLC-MS/MS
Molecular weight SEC 2D-SDS PAGE; HPLC-MS/MS
Hydrophobicity HIC -
One possible process design optimization procedure is the improvement of media components.
Media optimization is capable of changing the broth’s HCP composition towards a population that is
easier to separate or at least exhibits a lower HCP concentration. In addition, an optimized medium
not only shifts the HCP profile but also improves the cell growth and product titer, which is depicted
in Table 3 [47].
Table 3. Improved parameters by using an optimized medium according to [47].
Parameter Optimized medium
Titer increase Factor 2.5
Cell growth Factor 2–2.3
IgG/HCP 65%
HCP profile Shift
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A  schematic  overview  of  the  considered  alternative  process  as  well  as  process‐  and 
analysis‐related data are shown in Figure 6. 
Figure 5. Comparison of 2D-SDS PAGE of a reference (right) and optimized medium (left) during a
CHO cultivation according to [47]. Media was improved by a three-level DoE design.
In this work, the results of the characterization of the HCP profile from a mAb production process
are presented. Process-related data as well as analysis-related data are used for the characterization
of the process and for the classification of HCPs. The results of each analytical method are critically
evaluated in order to determine a process flow being suitable for USP DSP integration and process
optimization. Analytical methods such as SEC, 2D-PAGE, IEX, HIC as well as HPLC-MS/MS were
used in order to identify critical HCP in the cell-free broth and during each unit operation (i.e., ATPE,
IEX, and HIC).
2. Results and Discussion
A schematic overview of the considered alternative process as well as process- and analysis-related
data are shown in Figure 6.
The HCP criteria for an efficient DSP have to be evaluated for each unit operation, according to
Figure 4. Here, the classification of HCP focuses on the broth, the broth after diafiltration and on a side
component fraction after HIC separation. Process-related data such as titer, yield, and purity of each
unit operation are shown in Table 4.





Figure 6. Schematic overview of the considered alternative process in comparison of the benchmark manufacturing route. In addition, process and analysis related
data are shown and discussed in the text.
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This analytical procedure focuses on the classification and characterization of HCPs. Therefore,
each unit operation of the DSP has to be evaluated by its separation efficiency, using analytical
methods such as 2D-SDS PAGE, IEX, HIC, and SEC to determine HCP criteria for an efficient DSP,
as seen in Figure 3. Protein A and size-exclusion chromatography are used to determine yield and
purity, respectively. Each unit operation was loaded with the native broth in order to determine their
separation efficiency.
Table 4. Process related data of the cultivation, ATPE, and iCCC. Yield and purity were determined
using protein A chromatography and SEC, respectively.
Cultivation ATPE iCCC
System Mammalian cells PEG400/40 wt% PO4 IEX/HIC combination
Titer/yield 6.5 g/L >95% >95%
Log cell reduction 20.0 E6 cells/mL - 2.08 -
Purity <20% up to 80% * 100%
* Protein-based according to SEC.
The fraction number five occurring on the HIC was chosen due to the high side component
content near the target product, as seen in Figure 7. In the following, the classification of the HCPs will
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representing “Good”, “Bad,” and “Ugly” impurities. 
The  classification  criterion  of  the  considered HCP was  selected  by  comparing  their  pI  and 
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Figure 7. Chro atogra s of an analytical IEX (left) and IC (right) easure ent of the diafiltrated
cell-free CHO supernatant. The vertical sections represent the number of fractions taken, representing
“Good”, “Bad,” and “Ugly” impurities.
The classification criterion of the considered HCP was selected by comparing their pI and
molecular weight to the target product, as seen in Table 5.
Table 5. Classification of the “Good, Bad, and Ugly” HCP in comparison to the physicochemical
properties of the monoclonal antibody (mAb). MW, molecular weight; pI, isoelectric point.
Characteristic mAb Good Bad Ugly
MW [kDa] 144.2 <15 >15 >15
pI [−] 8.30 <4.75>10.00
4.75–7.30
9.30–10.00 7.30–9.30
While considering the 2D-PAGE gels, proteins with a MW lower than 15 kDa can be considered
“Good” since they can be separated by using diafiltration subsequent to an ATPE with a suitable MW
cutoff. Therefore, this filtration step is coupled to a buffer change, which is necessary for the use of
the iCCC, since the specific light phase contains PEG400, resulting in a more viscous solution, which
would make the chromatographic steps more difficult to handle.















pI  of  4.75  can  be  subjected  to  a  possible  precipitation  step  using  hydrochloric  acid,  which 
significantly reduces their concentration [42]. Those impurities exhibit a different pI than the target 
protein  and  can  efficiently  be  separated  by  an  IEX  and  are  therefore  classified  as  “Good.” 
Experimental IEX data show a distinctly different interaction with the stationary phase due to their 
surface charge distribution, as seen in Figure 9, which resemble the “Good” HCP. They elute near 
the void volume and  can be easily  separated. A  similar  train of  thought  can be  conducted while 




Impurities with  a  pI  range  close  to  the  target  protein  (i.e.,  7.30–9.30)  are more  difficult  to 
separate via an IEX and are therefore considered “Ugly.” However, since the separation efficiency of 
the  IEX will depend on  the column, buffer solution, and process parameters,  this  range can vary 
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Figure 8. 2D SDS-PAGE of the broth, diafiltrated broth (DF) and HIC fraction. Green circles represent
“Good”, yellow circles “Bad,” and red circles “Ugly” HCP.
Proteins larger than 15 kDa have to be separated by another unit operation, which is based on
other physicochemical properties (i.e., pI, hydrophobi ity). Th refore, “Bad” and “Ugly” proteins
possess a MW larger than 15 kDa. The horizontal line at 150 kDa represents the target protein in its
functional condition. The vertical lines depict the iso lectric point at 4.75 nd 7.0. Impurities with a pI
of 4.75 can be subjected to a possible precipitation step using hydrochloric acid, which significantly
reduces their concentration [42]. Th s impurities exhibit a different pI than t e target protein and can
efficiently be separated by an IEX and are therefore classified as “Good.” Experimental IEX data show
a distinctly different interaction with the stationary phase due to their surface charge distribution,
as seen in Figure 9, which r semble the “Good” HCP. They elute near the void volume and can be easily
separated. A similar train of thought can be conducted while characterizing the HIC chromatogram.
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Figure 9. Chromat gram of t (left) and HIC (right) after various cycles in the iCCC mode.
Impurities with a pI range cl se to the target protein (i.e., 7.30–9.30) are more difficult to separate
via an IEX and are therefore considered “Ugly.” However, since the separation efficiency of the IEX
will depend on the column, buffer solution, and process par meters, this range can vary depending on
the system use . Impurities with charact ristics in between those of “Good” and “Ugly” are defined
as “Bad.” They ss ss a pI f 4.75–7.30 nd 9.30–10.00 a d can be difficu t o s parate when other
physicochemical properties (i.e., hydrophobicity) resemble the target product. This depen ency can
of course also occur with “Ugly” HCP but since they are already classified as difficult to separate,
they will not be characterized differently. Regarding the “Good” HCP, this dependency will not
occur even if other physicochemical properties show close similarity to the product, since at least
one physicochemical attribute is significantly different from the target product. The pI is restricted to
10 due to the pH gradient used in the IEF prior to 2D gel electrophoresis.
The 2D-PAGE analysis seen in Figure 8 is suitable for the visualization of the side component
spectrum. However, the sample preparation requires reducing agents such as DTT, which destroys the
protein’s structure by reducing the disulfide bonds. This preparation procedure results in spots on the
gel, which do not resemble their native structure in the supernatant. Following the aforementioned
classification and separation system, proteins with a MW lower than 15 kDa but with an isoelectric
point near the target product will sometimes be classified as “Good” since they can be separated by
filtration. Hence, the native protein can be “Ugly” even if it appears as “Good” in the gel (assuming no
change in surface charge). Thus, it is of the utmost importance to use orthogonal analytical methods
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to validate the classification. In terms of MW, SEC analysis can be conducted in order to determine
the size distribution of side components, as seen in Figure 10. The advantage of using SEC analysis is
the determination of the side component’s native MW distribution as well as their qualitative mass in
proportion to the product’s signal. The disadvantage is the less sensitive detection of low mass content
side components as well as proteins resulting in a signal overlap with the mAb.
In order to identify proteins present in the 2D-PAGE gel spots, their tryptic peptides were
identified via analysis with liquid chromatography (LC) coupled to tandem mass spectrometry
(MS/MS) and a database search. The numbers in the gels in Figure 8 indicate the spots that were
analyzed using LC-MS/MS. The first five spots occurred in every gel. The subsequent spots were
unique in each gel. The identified peptides and their corresponding proteins of each spot in these gels
are presented in the appendix (Tables A1–A3). The identified proteins of the first recurrent spots are
listed alongside with their MW and pI in Table 6.
As can be seen in Table 6, the MW and pI of the spots analyzed with 2D-PAGE do not correspond
to the value in the protein database. This is a result of proteins existing in different species due to
posttranslational modifications and proteolytic processing (proteolytic degradation and sample
preparation, respectively). In contrast, the theoretically calculated pI values obtained by the ExPASy
computation tool (http://web.expasy.org/compute_pi/) represent the unmodified full length amino
acid sequence of a defined protein. SEC analysis, for example, is a non-invasive analytical method for
the determination of MW distribution of side components, if the salt concentration used in aqueous
eluents allows for separation based on molecular size exclusion alone due to the hydrodynamic
radius [48]. Nevertheless, for a systematic integration approach, the classification of HCPs based on
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Figure 10. SEC chromatograms after various cycles as well as the broth after diafiltration.
Table 6. Classification of CHO proteins identified via LC-MS/MS analysis and characterized by
2D-PAGE gel. Comparison of theoretical (UniProt; pI calculated according to the amino acid sequences)














1 25 7.0 Bad 81.56 5.69 Bad Glutathione S-transferaseMu7-like protein A0A061IN16
2 25 7.5 Ugly 102.7 6.02 Bad Actin, cytoplasmic 1 A0A069C7Y3
3 30 7.6 Ugly 38.03 6.08 Bad Purine nucleosidephosphorylase-like protein A0A061ILE8
4 50 9.4 Bad 72.13 7.23 Ugly Pyruvate kinase A0A098KXF7
5 25 6.3 Bad 38.03 6.08 Bad Purine nucleosidephosphorylase-like protein A0A061ILE8
1 Theoretical values according to the unmodified full length protein according to UniProt; 2 Theoretical values
calculated using the ExPASy computation tool (http://web.expasy.org/compute_pi/).
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3. Materials and Methods
Chinese hamster ovary cells (CHO DG44) were used for the production of a monoclonal antibody.
The culture conditions were 37 ◦C, 5% carbon dioxide, and 130 rpm. The cultivations were carried out
in shake flasks in a serum-free medium.
The ATP system applied consisted of 44.5% broth, 15.5% PEG400 (Merck KGaA, Darmstadt,
Germany), and 40% of a 40 wt% phosphate buffer. All the components were weighed. The extraction
was carried out at pH 6.0 in 50-mL beakers at room temperature. The system was mixed for 15 min at
140 rpm in an incubator shaker. Phase separation took place within 30 min in a separatory funnel.
The broth was diafiltrated using a SARTOFLOW® Slice 200 Benchtop system from Sartorius
Stedim (Germany). A 10 kDa Hydrosart® (Sartorius Stedim, Göttingen, Germany) was utilized as a
membrane module.
The iCCC (integrated counter-current chromatography) is run by using Fractogel® EMD SO3−(s)
and Fractogel® EMD Phenyl(s) (Merck KGaA, Darmstadt, Germany). The buffers consisted of a 20 mM
sodium phosphate buffer (Na2HPO4, NaH2PO4) as well as a 20 mM sodium phosphate buffer with
1 M Na2SO4.
The product was quantified by Protein A chromatography (PA ID Sensor Cartridge, Applied
Biosystems, Bedford, MA, USA). Dulbecco’s PBS buffer (Sigma-Aldrich, St. Louis, MO, USA) was
used as a loading buffer at pH 7.4 and as an elution buffer at pH 2.6. The absorbance was monitored at
280 nm.
The size exclusion chromatography was done by using a Yarra™ 3 µm SEC-3000
column (Phenomenex Ltd., Aschaffenburg, Germany) with 0.1 M Na2SO4, 0.1 M Na2HPO4,
and 0.1 M NaH2PO4 (Merck KGaA, Germany) as a buffer system.
Isoelectric focusing was carried out using IPG strips (ReadyStripTM IPG Strips, linear, pH 3–10,
BIO-RAD, Hercules, CA, USA) and an isoelectric focusing unit of Hoefer (Hoefer Inc., Holliston, MA,
USA). A subsequent SDS PAGE was carried out using gels (Criterion TGX Precast Gel, 4–15% Bis-Tris,
BIO-RAD), buffers, and an electrophoresis chamber from BIO-RAD. The resulting gels were colored by
Coomassie Brilliant Blue G-250 (VWR International, Radnor, PA, USA).
For the identification of proteins, selected 2D GE spots were cut out and reduced into 1-mm2
pieces. After reduction of the disulfide bonds with 10 mM DL-dithiothreitol (Sigma-Aldrich) and
alkylation with 50 mM iodoacetamide (Sigma-Aldrich), an in-gel proteolytic digestion was performed
with 8 ng/µL trypsin (Promega, Madison, WI, USA) at 37 ◦C overnight. The peptides were extracted
from the gel with 65% acetonitrile and 5% acetic acid in water and the solvent was evaporated to
complete dryness. The peptides were re-suspended in 20 µL 0.1% formic acid (Fluka) and subjected
to LC-MS/MS analysis with a nano-flow ultra-performance liquid chromatography (nano-UPLC)
system (nanoACQUITY, Waters, Manchester, UK) coupled via an electrospray-ionization (ESI) source
to a tandem mass spectrometer (MS/MS) consisting of a quadrupole and a orbitrap mass analyzer
(Orbitrap QExcactive, Thermo Scientific, Bremen, Germany). Four microliters of each sample were
loaded onto a reversed-phase (RP) trapping column (Symetry C18 Trap Column; 100 Å, 5 µm,
180 µm × 20 mm) and washed with 1% buffer B for 5 min. The peptides were eluted onto a RP
capillary column (nanoAcquity Peptide BEH analytical column; 130 Å, 1.7 µm, 75 µm × 200 mm) and
separated by a gradient from 3 to 35% buffer B in 35 min (250 nL/min). Eluting peptides were ionized
and desorbed by ESI in the positive mode using a fused-silica emitter (I.D. 10 µm, New Objective,
Woburn, MA, USA) at a capillary voltage of 1800 V. Data-dependent acquisition mode was used
with the following parameters: MS level over a m/z range from 400 to 1500, with a resolution of
70,000 FWHM at m/z 200. Maximum injection time was set to 120 ms for an AGC target of 1E6. For
MS/MS analysis the top 12 signals were isolated in a 2 m/z window and fragmented with a normalized
HCD collision energy of 25. Fragment spectra were recorded with a resolution of 17,500 FWHM at
m/z 200. Maximum injection time was set to 60 ms for an AGC target 5E5.
LC–MS raw data were processed with MaxQuant (Max Planck Institute of Biochemistry, Planegg,
Germany) algorithms (version 1.5.8.3). Protein identification was carried out with Andromeda against
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a hamster (Cricetulus griseus) (www.uniprot.org, downloaded on 31 January 2017) and a contaminant
database. The searches were performed using a precursor mass tolerance set to 10 ppm and fragment
mass tolerance set to 20 ppm. For peptide identification, two missed cleavages were allowed,
a carbamidomethylation on the cysteine as a fixed modification and oxidation of the methionine
as a variable modification. A maximum of five modifications per peptide were allowed.
4. Conclusions
The presented approach of integrating USP and DSP is based on the classification and
characterization of impurities generated during USP. This will lead to a deeper quantitative process
understanding and identification of issues in the DSP early on. Here, the HCPs were categorized
into “The Good, the Bad, and the Ugly” by evaluating their physicochemical properties compared
to the monoclonal antibody. In this approach “Good” impurities possess a MW lower than 15 kDa
and a pI lower than 4.75. “Ugly” impurities on the other hand exhibit a pI of 7.3–9.3, whereas “Bad”
impurities feature a pI between 4.75 and 7.3 as well as between 9.3 and 10.0. In order to evaluate the
classification system for the generated HCPs, orthogonal analytical methods are of utmost importance.
IEX and SEC analysis were conducted for the identification of impurities. Theoretical pI and MW
calculated based on the amino acid sequence differ from the experimental values obtained in 2D gel
electrophoresis. This is due to not considering posttranslational modifications, as well as in vivo and
ex vivo proteolytic processing.
Nevertheless, it is possible to characterize HCP based on pI and MW properties. In order to fully
categorize the separation efficiency of each unit operation in the DSP as well as of their combinations,
the HCP profile has to be determined with the aforementioned analytical methods in future approaches.
This portfolio can of course be extended by adding supplementary methods like NMR technologies,
preferably online [49].
Considering the significant amount of work in terms of characterization, monitoring, and removal
of impurities and contaminations created by the USP step, as well as the time and cost associated
with their removal, it may be worthwhile to reflect in more detail how these impurities and product
variations are generated in the first place. Work to this end already started some time ago. Initial results
and corresponding concepts for a more balanced integrated process design will be presented in the
near future.
Acknowledgments: The authors would especially like to acknowledge Petra Gronemeyer (now Boehringer/
Biberach) for her outstanding contribution to this topic during her PhD studies, for which she has been highly
esteemed at conferences.
Author Contributions: Martin Kornecki conceived and designed the experiment as well as wrote the paper.
Martin Kornecki performed the SDS-PAGE experiments. Fabian Mestmäcker performed the chromatographic
(iCCC, IEX, HIC) experiments. Laura Heikaus de Figueiredo performed the LC-MS/MS experiments and analyzed
the data. All mentioned authors interpreted the data. Hartmut Schlüter as well as Jochen Strube substantively
revised the work and contributed the materials and analysis tools. Jochen Strube is responsible for conception
and supervision.
Conflicts of Interest: The authors declare no conflict of interest.
Antibodies 2017, 6, 13 13 of 18
Appendix A
Table A1. Peptides and their corresponding proteins identified via LC-MS/MS in spots of 2D gel of the broth. Molecular weight (MW) and isoelectric point (pI) of the
unmodified full length protein according to UniProt.
# Gel MW Gel pI MW (UniProt) pI (UniProt) Primary Accession Number (UniProt) Number of Unique Peptides Protein
1 25 7.2 25.76 6.45 A0A061HUZ2 9 Platelet-activating factor
81.56 5.69 A0A061IN16 11 Glutathione S-transferase Mu 7-like protein
25.88 6.43 A0A061HYZ1 9 Peroxiredoxin-6-like protein
2 25 7.9 30.28 7.22 A0A061IFC9 4 Carbonic anhydrase
89.52 6.23 A0A061IJC4 4 Glutathione S-transferase Mu 1-like protein
81.56 5.69 A0A061IN16 4 Glutathione S-transferase Mu 7-like protein
3 30 7.6 72.13 7.23 A0A098KXF7 8 Pyruvate kinase
38.03 6.08 A0A061ILE8 6 Purine nucleoside phosphorylase-like protein
32.23 9.11 A0A061IAK4 5 L-lactate dehydrogenase A chain
4 50 9.6 45.28 8.48 A0A061IB69 7 Fructose-bisphosphate aldolase
72.13 7.23 A0A098KXF7 15 Pyruvate kinase
102.7 6.02 A0A069C7Y3 5 Actin, cytoplasmic 1
5 25 6.6 27.39 6.34 A0A061I2E1 8 Proteasome subunit
89.52 6.23 A0A061IJC4 8 Glutathione S-transferase Mu 1-like protein
81.56 5.69 A0A061IN16 8 Glutathione S-transferase Mu 7-like protein
6 45 6.7 50.57 5.93 G3GR73 11 Rab GDP diss. inhib.
52.79 6 A0A098KXB1 10 Cytosol aminopeptidase-like protein
44.67 7.54 A0A061IJI8 9 Alpha-enolase
7 50 6.1 52.79 6 A0A098KXB1 20 Aminopeptidase
72.13 7.23 A0A098KXF7 29 Pyruvate kinase
145.1 8.37 A0A061HU29 15 Glucose-6-phosphate 1-dehydrogenase
8 57 6 73.86 5.56 A0A061I5D1 22 Heat shock protein
74.72 5.29 A0A061HWC7 9 Plastin-3
69.64 5.57 A0A061I5U1 9 Heat shock-related protein 2
9 80 6.1 72.13 7.23 A0A098KXF7 11 Pyruvate kinase
117.7 5.42 G3IBG3 8 Ubiquitin activating enzyme E1
73.86 5.56 A0A061I5D1 7 Heat shock protein
10 70 5.6 73.86 5.56 A0A061I5D1 9 Heat shock protein
68.43 5.55 A0A061I1Q2 5 Vitamin K-dependent protein S
85.71 5.2 A0A061IAX6 5 Dipeptidyl peptidase 3
11 25 6 25.88 6.43 A0A061HYZ1 9 Peroxiredoxin
89.52 6.23 A0A061IJC4 19 Glutathione S-transferase Mu 1-like protein
81.56 5.69 A0A061IN16 14 Glutathione S-transferase Mu 7-like protein
12 55 7.8 72.13 7.23 A0A098KXF7 37 Pyruvate kinase
52.79 6 A0A098KXB1 10 Cytosol aminopeptidase-like protein
73.86 5.56 A0A061I5D1 4 Heat shock protein
13 50 8.6 52.79 6 A0A098KXB1 4 Cytosol aminopeptidase-like protein
72.13 7.23 A0A098KXF7 19 Pyruvate kinase
145.1 8.37 A0A061HU29 2 Glucose-6-phosphate 1-dehydrogenase
14 50 9.2 72.13 7.23 A0A098KXF7 20 Pyruvate kinase
44.67 7.54 A0A061IJI8 3 Alpha-enolase
42.69 8.78 A0A061HV36 3 Eukaryotic translation initiation factor 2 subunit 3-like protein
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Table A2. Peptides and their corresponding proteins identified via LC-MS/MS in spots of 2D gel of the diafiltrated broth. Molecular weight (MW) and isoelectric
point (pI) of the unmodified full length protein according to UniProt.
# Gel MW Gel pI MW (UniProt) pI (UniProt) Primary accession number (UniProt) Number of Unique Peptides Protein
1 25 7 26.96 5.38 A0A061I6A0 5 Glutathione S-transferase A4-like protein
81.56 5.69 A0A061IN16 8 Glutathione S-transferase Mu 7-like protein
38.03 6.08 A0A061ILE8 8 Purine nucleoside phosphorylase-like protein
2 25 7.5 38.03 6.08 A0A061ILE8 6 Purine nucleoside phosphorylase
102.7 6.02 A0A069C7Y3 2 Actin, cytoplasmic 1
43.35 6.48 A0A061IJG8 2 Prostaglandin reductase 1-like protein
3 30 7.4 45.28 8.48 A0A061IB69 1 Fructose-bisphosphate aldolase
4 50 9.4 89.52 6.23 A0A061IJC4 2 Glutathione S-transferase
5 25 6.6 38.03 6.08 A0A061ILE8 7 Purine nucleoside phosphorylase
89.52 6.23 A0A061IJC4 5 Glutathione S-transferase
6 37 9.4 45.28 8.48 A0A061IB69 4 Fructose-bisphosphate aldolase
43.35 6.48 A0A061IJG8 2 Prostaglandin reductase 1-like protein
361.89 4.81 A0A061IH02 2 Desmoglein-4-like protein
7 30 7 38.03 6.08 A0A061ILE8 4 Purine nucleoside phosphorylase
128.68 6.78 A0A061IK77 3 Exosome component 10 isoform 1
11.37 11.36 G3H2T6 2 Histone H4
8 30 6.8 27.79 4.7 A0A061IGS6 4 Protein sigma
102.7 6.02 A0A069C7Y3 5 Actin, cytoplasmic 1
361.89 4.81 A0A061IH02 4 Desmoglein-4-like protein
9 17 6.6 11.37 11.36 G3H2T6 4 Histone H4
14.99 10.2 A0A061IP52 2 Histone H2B
10 30 5.6 52.25 5.35 A0A061IML2 13 Annexin
268.7 5.69 A0A061IP39 10 Filamin-B isoform 4
50.99 6.94 A0A061I8I4 4 Cathepsin F
11 30 4.5 52.25 5.35 A0A061IML2 2 Annexin
14.73 9.87 A0A061IQB8 3 Ubiquitin-60S
12 30 2.8 38.03 6.08 A0A061ILE8 8 Purine nucleoside phosphorylase
89.52 6.23 A0A061IJC4 8 Glutathione S-transferase
101.51 5.12 A0A061IRD9 5 AP complex subunit beta
13 15 6.7 38.03 6.08 A0A061ILE8 4 Purine nucleoside phosphorylase
89.52 6.23 A0A061IJC4 4 Glutathione S-transferase
38.31 5.33 A0A061IEW1 3 Nuclear migration protein nudC-like protein
14 15 6.1 38.31 5.33 A0A061IEW1 5 Nuclear migration protein nudC-like protein
89.52 6.23 A0A061IJC4 4 Glutathione S-transferase
54.11 5.01 A0A061IDB2 3 Prelamin-A/C-like isoform 1
15 12 5.6 17.16 7.8 A0A061I0I3 4 SH3 binding protein
17.19 5.94 G3HBD4 3 Nucleoside diphosphate kinase
16 17 6.6 23.42 5.1 G3GXB0 3 Rho GDP
89.52 6.23 A0A061IJC4 8 Glutathione S-transferase
102.7 6.02 A0A069C7Y3 2 Actin, cytoplasmic 1
17 16 9.2 14.73 9.87 A0A061IQB8 3 Ubiquitin-60S
102.7 6.02 A0A069C7Y3 3 Actin, cytoplasmic 1
23.42 5.1 G3GXB0 3 Rho GDP
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Table A3. Peptides and their corresponding proteins identified via LC-MS/MS in spots of 2D gel of the HIC fraction. Molecular weight (MW) and isoelectric point (pI)
of the unmodified full length protein according to UniProt.
# Gel MW Gel pI MW (UniProt) pI (UniProt) Primary Accession Number (UniProt) Number of Unique Peptides Protein
1 25 6.9 - - - - -
2 25 7.6 11.37 11.36 G3H2T6 2 Histone H4
102.7 6.02 A0A069C7Y3 2 Actin, cytoplasmic 1
3 30 7.6 38.03 6.08 A0A061ILE8 2 Purine nucleoside
102.7 6.02 A0A069C7Y3 1 Actin, cytoplasmic 1
4 50 8.4 44.67 7.54 A0A061IJI8 8 Alpha-enolase
72.13 7.23 A0A098KXF7 8 Pyruvate kinase
38.03 6.08 A0A061ILE8 2 Purine nucleoside
5 25 6.3 38.03 6.08 A0A061ILE8 6 Purine nucleoside
6 25 8.4 38.03 6.08 A0A061ILE8 4 Purine nucleoside
7 50 8 44.67 7.54 A0A061IJI8 1 Alpha-enolase
8 47 7.6 44.67 7.54 A0A061IJI8 5 Alpha-enolase
102.7 6.02 A0A069C7Y3 3 Actin, cytoplasmic 1
72.13 7.23 A0A098KXF7 2 Pyruvate kinase
9 50 7.2 59.76 9.22 A0A061ICE4 4 ATP synthase subunit
14.73 9.87 A0A061IQB8 2 Ubiquitin-60S ribosomal protein L40-like isoform 2
102.7 6.02 A0A069C7Y3 2 Actin, cytoplasmic 1
10 25 5.1 - - - - -
11 50 4.8 211.66 5.42 A0A061I4N6 1 CAP-Gly domain-containing linker protein 1
12 52 4 - - - - -
(-) Spots, which were not able to be identified.
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